Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus CEPTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus CEPTAZ.
CEFAZOLIN IN DEXTROSE vs CEPTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
None Documented
None Documented
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic